Analysis of 154 lung cancer brain metastases revealed greater tumor heterogeneity than primary tumors, with shared mutations (TTN, TP53), enhanced mitochondrial metabolism but suppressed immunity; combining mitochondrial-targeting drugs with immunotherapy improved mouse survival [117]. This evidence concerns the gene TP53 and lung carcinoma.